Humanwell Healthcare (Group) Co.,Ltd. (SHA: 600079)

Market Cap	30.73B
Revenue (ttm)	25.00B
Net Income (ttm)	1.92B
Shares Out	1.61B
EPS (ttm)	1.18
PE Ratio	16.19
Forward PE	12.50
Dividend	0.30 (1.57%)
Ex-Dividend Date	Jun 24, 2024

Volume	16,361,393
Open	19.59
Previous Close	19.59
Day's Range	18.98 - 19.74
52-Week Range	15.68 - 27.36
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2024

About Humanwell Healthcare (Group) Co.,Ltd.

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia with artificial respiration; remifentanil hydrochloride for Injection for induction of general anesthesia; hydromorphone hydrochloride injection For patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injection for general anesthesia induction...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 17,676
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600079

Financial Performance

In 2023, 600079's revenue was 24.52 billion, an increase of 9.79% compared to the previous year's 22.34 billion. Earnings were 2.13 billion, a decrease of -14.07%.